Page 2 - Tolerability News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Tolerability. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Tolerability Today - Breaking & Trending Today

Current Treatment Options in Second-line FL

Experts on follicular lymphoma discuss second-line treatment options available for patients. ....

Recent Updates , Follicular Lymphoma , Mantle Cell Lymphoma , Treatment Options , Second Line Therapy , Overall Survival , Cart Cell Therapy , T Cell Engager , Cytokine Release Syndrome ,

Mitapivat Maintains Safety, Tolerability Over 2 Years in Sickle Cell Disease

Extension analysis from a phase 1 trial show the investigative oral mitapivat was not associated with any discontinuations nor deaths over 2 years. ....

San Diego , United States , National Institutes Of Health , Sickle Cell Branch Of The National Heart , Lung Blood Institute , American Society Of Hematology , Swee Lay Thein , American Society , National Institutes , Sickle Cell Branch , National Heart , Blood Institute , Sickle Cell Disease , Sickle Cell , Phase 1 , Mash 2023 ,

Safety of JAK Inhibitors Approved for AD Treatment

Expert dermatologists review the safety data of the current JAK inhibitors approved for AD, highlighting adverse events and long-term safety data. ....

Christopher Bunick , Alexandra Golant , Lisa Swanson , Peter Lio , Jak Inhibitors , Atopic Dermatitis , Safety Profile , Side Effects , Lab Monitoring , Long Term Safety , Boxed Warning ,

The Safety and Efficacy of Novel SD Treatment

Dermatologists discuss the safety and efficacy of roflumilast for seborrheic dermatitis (SD), highlighting its tolerability across backgrounds and age groups, safety in pediatric care, and the unmet need it fulfills. ....

South Australia , Neal Bhatia , Shawn Kwatra , Stein Gold , Seborrheic Dermatitis , Pediatric Patients , Safety Profile ,

Treatment Choices for Recurrent dMMR Endometrial Cancer

Exploring treatment options for patients with recurrent mismatch repair deficient endometrial cancer, including the choice between single-agent checkpoint inhibitors and chemo-immunotherapy combinations, with insights from GARNET and KEYNOTE-158 studies. ....

Optimizing Therapy , Endometrial Cancer , Recent Data Highlights , Recurrent Endometrial Cancer , Mismatch Repair Deficiency , Treatment Recommendations , Checkpoint Inhibitors , Platinum Based Regimen , Response Rate , Duration Of Response , Keynote 158 , Overall Survival , Treatment Options , Lenvatinib Pembrolizumab , Second Line Treatment , Treatment Impact , Overall Survival Data ,